{"@id":"https://bioecon.ru/technology/viro-immunotherapeutics/","@type":"Technology","cluster":"regenerative-personalized","formats":{"html":"https://en.bioecon.ru/technology/viro-immunotherapeutics/","json":"https://en.bioecon.ru/api/v1/technology/viro-immunotherapeutics/index.json"},"id":"viro-immunotherapeutics","industries":["pharma","biomanufacturing"],"lang":"en","links":{"industries":["https://bioecon.ru/industries/pharma/","https://bioecon.ru/industries/biomanufacturing/"],"suppliers":["https://bioecon.ru/companies/novartis/","https://bioecon.ru/companies/esco-aster/","https://bioecon.ru/companies/orf-genetics/","https://bioecon.ru/companies/agc-biologics/","https://bioecon.ru/companies/genscript-probio-genscript/","https://bioecon.ru/companies/astrazeneca/","https://bioecon.ru/companies/spiber-technologies-ab/","https://bioecon.ru/companies/loopworm/"]},"maturity":7,"name":"Viro-Immunotherapeutics","regions":["ch","eu","us","cn"],"risk":"medium","section":"technology","sector":"health-biomedicine","sources":[{"date":"2026-11-22","entity":"Swiss Biotech Directory 2026","kind":"vendor","urls":["https://www.swissbiotech.org/directory/"]}],"stages":[{"n":1,"title":"Viral genome attenuation"},{"n":2,"title":"Immunostimulatory transgene arming"},{"n":3,"title":"Intratumoral or systemic delivery"},{"n":4,"title":"In-situ tumor lysis and abscopal effect"}],"summary":"Recombinant tumor-selective oncolytic viruses (herpes simplex, vesicular stomatitis, adenoviruses) engineered with genetic deletions restricting replication to p53/Rb-deficient cancer cells while armed with GM-CSF, IL-12, or BiTE payloads to provoke catastrophic in-situ tumor lysis and systemic neoantigen immunity.","url":"/technology/viro-immunotherapeutics/","verified":"2026-11-22"}